8 research outputs found
Kinetics of the number of antigen-specific memory B-cells detected in the peripheral blood of infants after immunisation with different schedules of MenC conjugate vaccines, at each time-point following primary and booster vaccines, based on geometric mean concentrations for each study group at each visit.
<p>Kinetics of the number of antigen-specific memory B-cells detected in the peripheral blood of infants after immunisation with different schedules of MenC conjugate vaccines, at each time-point following primary and booster vaccines, based on geometric mean concentrations for each study group at each visit.</p
Number of MenC-specific memory B-cells (log<sub>10</sub> scale) detected in the peripheral blood of individual participants after immunisation with different schedules of MenC conjugate vaccines, at each time-point following infant primary and booster vaccines.
<p>Number of MenC-specific memory B-cells (log<sub>10</sub> scale) detected in the peripheral blood of individual participants after immunisation with different schedules of MenC conjugate vaccines, at each time-point following infant primary and booster vaccines.</p
Comparison between groups of the log<sub>10</sub> transformed number of MenC-specific memory B-cells detected in the peripheral blood at each visit.
<p>1-dose CRM: 1 dose MenC-CRM<sub>197</sub> at 3 months of age; 2-dose CRM: 2 doses of MenC-CRM<sub>197</sub> at 3 and 4 months of age; Control: No MenC primary vaccine doses; 1-dose TT: 1 dose MenC-TT at 3 months of age.</p><p>*Results of the analysis of pairs of groups are provided in Table S1 in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0101672#pone.0101672.s003" target="_blank">file S1</a>.</p
Number of MenC-specific memory B-cells detected in the peripheral blood of infants 6 days after a Hib-MenC-TT booster at 12 months of age, according to different primary immunisation schedules (magnified from <b>Figure 3</b>).
<p>Number of MenC-specific memory B-cells detected in the peripheral blood of infants 6 days after a Hib-MenC-TT booster at 12 months of age, according to different primary immunisation schedules (magnified from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0101672#pone-0101672-g003" target="_blank"><b>Figure 3</b></a>).</p
Schedule of study visits and procedures, including vaccines administered and timing of blood draws used to measure MenC-specific memory B-cells.
<p>Schedule of study visits and procedures, including vaccines administered and timing of blood draws used to measure MenC-specific memory B-cells.</p
Number of children enrolled and included in the final analysis for MenC-specific memory B-cells.
<p>Number of children enrolled and included in the final analysis for MenC-specific memory B-cells.</p
Proportion of MenC-specific memory B-cells out of the total pool of IgG positive memory B-cells detected in the peripheral blood at each time-point.
<p>IQR: Interquartile range.</p
Mean Anti-Hib Antibody Concentrations and Percentage of Participants with Protective Levels.
<p>Only 20% of children under 5 years old have protective (>0.15 µg/ml) antibody levels, rising to 83% of 15–54 year-olds. Geometric mean anti-polyribosylribitol phosphate IgG concentrations for each age group are plotted on the left y-axis (±SE). The percentage of participants with antibody concentrations >0.15 µg/ml (‘short-term protection’: the height of the entire column) and >1 µg/ml (‘long-term’ protection: the height of only the shaded column) are plotted on the right y-axis (±SE). Sample sizes (n): Cord Blood (n = 15); 0.5–4 yrs (n = 15); 5–7 yrs (n = 15); 8–14 yrs (n = 18); 15–54 yrs (n = 12); 55–77 yrs (n = 11).</p